211 related articles for article (PubMed ID: 38539495)
21. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
22. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Ravandi F; Estey E; Jones D; Faderl S; O'Brien S; Fiorentino J; Pierce S; Blamble D; Estrov Z; Wierda W; Ferrajoli A; Verstovsek S; Garcia-Manero G; Cortes J; Kantarjian H
J Clin Oncol; 2009 Feb; 27(4):504-10. PubMed ID: 19075265
[TBL] [Abstract][Full Text] [Related]
23. The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome.
LaBella D; Regan S; Konig H; Egan DN; Bailey NA; Mawad R; Gilbert M; Pagel JM; Pu JJ
Front Oncol; 2022; 12():911745. PubMed ID: 35992790
[TBL] [Abstract][Full Text] [Related]
24. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
25. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).
Wang HY; Gong S; Li GH; Yao YZ; Zheng YS; Lu XH; Wei SH; Qin WW; Liu HB; Wang MC; Xi JY; Chen LM; Zhang M; Zhang XX; Zhang HY; Zhang CS; Wald DN; Zhu HH; Liu L; He PC
Blood Cancer J; 2022 Nov; 12(11):158. PubMed ID: 36404343
[TBL] [Abstract][Full Text] [Related]
26. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
Ma Y; Liu L; Jin J; Lou Y
PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027
[TBL] [Abstract][Full Text] [Related]
27. Molecular remission as a therapeutic objective in acute promyelocytic leukemia.
Cicconi L; Fenaux P; Kantarjian H; Tallman M; Sanz MA; Lo-Coco F
Leukemia; 2018 Aug; 32(8):1671-1678. PubMed ID: 30026570
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia.
Yoo ES
Korean J Pediatr; 2011 Mar; 54(3):95-105. PubMed ID: 21738538
[TBL] [Abstract][Full Text] [Related]
29. Acute Promyelocytic Leukemia: A History over 60 Years-From the Most Malignant to the most Curable Form of Acute Leukemia.
Thomas X
Oncol Ther; 2019 Jun; 7(1):33-65. PubMed ID: 32700196
[TBL] [Abstract][Full Text] [Related]
30. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
31. Chromosomal abnormality of acute promyelocytic leukemia other than
Imataki O; Uemura M
BMC Clin Pathol; 2016; 16():16. PubMed ID: 27708545
[TBL] [Abstract][Full Text] [Related]
32. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
[TBL] [Abstract][Full Text] [Related]
33. Acute Promyelocytic Leukemia with del(6)(p22) and Atypical bcr2 PML::RARA Fusion Transcript: A Case Report.
Lauricella C; Greco R; Mancini V; Motta V; Ciraolo A; De Canal G; De Paoli E; Paglino G; Guido V; Bonoldi E; Veronese S; Soriani S
Acta Haematol; 2023; 146(1):58-64. PubMed ID: 36198282
[TBL] [Abstract][Full Text] [Related]
34. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
35. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
36. [The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
Lu Y; Li F; Mu Q; Meng H; Qian W; Tong H; Mai W; Pei R; Yu M; Zhao X; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):372-7. PubMed ID: 26031521
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
38. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
39. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
40. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.
Lengfelder E; Hofmann WK; Nowak D
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1035-43. PubMed ID: 24053202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
